

SADBE, and TCA, and we therefore propose to include them on the 503B Bulks List as described in this notice.

At this time, we find no basis to conclude that there is a clinical need for outsourcing facilities to compound drug products using the bulk drug substances diazepam, dobutamine HCl, dopamine HCl, edetate calcium disodium, folic acid, glycopyrrolate, hydroxyzine HCl, ketorolac tromethamine, labetalol HCl, mannitol, metoclopramide HCl, moxifloxacin HCl, nalbuphine HCl, polidocanol, potassium acetate, procainamide HCl, sodium nitroprusside, sodium thiosulfate, and verapamil HCl. We therefore propose not to include these bulk drug substances on the 503B Bulks List.

## VII. References

The following references marked with an asterisk (\*) are on display at the Dockets Management Staff (see **ADDRESSES**) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at <https://www.regulations.gov>. References without asterisks are not on public display at <https://www.regulations.gov> because they have copyright restriction. Some may be available at the website address, if listed. References without asterisks are available for viewing only at the Dockets Management Staff. FDA has verified the website addresses, as of the date this document publishes in the **Federal Register**, but websites are subject to change over time.

\*1. FDA, Guidance for Industry, "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act," January 2017 (available at <https://www.fda.gov/media/94402/download>).

\*2. FDA, Guidance for Industry, "Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act," March 2019 (available at <https://www.fda.gov/media/121315/download>).

\*3. FDA Memorandum to File, Clinical Need for Diphenylcyclopropanone (DPCP) in Compounding Under Section 503B of the FD&C Act, July 2020.

\*4. FDA Memorandum to File, Clinical Need for Glycolic Acid in Compounding Under Section 503B of the FD&C Act, July 2020.

\*5. FDA Memorandum to File, Clinical Need for Squaric Acid Dibutyl Ester (SADBE) in Compounding Under Section 503B of the FD&C Act, July 2020.

\*6. FDA Memorandum to File, Clinical Need for Trichloroacetic Acid (TCA) in Compounding Under Section 503B of the FD&C Act, July 2020.

7. Lehet, T.M., A. El Tawdy, R.M. Abdel Hay, and S. Farid, 2011, "Percutaneous

Collagen Induction Versus Full-Concentration Trichloroacetic Acid in the Treatment of Atrophic Acne Scars," *Dermatologic Surgery*, 37(2):207–216.

8. Kumari, R. and D.M. Thappa, 2010, "Comparative Study of Trichloroacetic Acid Versus Glycolic Acid Chemical Peels in the Treatment of Melasma," *Indian Journal of Dermatology, Venereology and Leprology*, 76:447, available at <http://www.ijdvl.com/text.asp?2010/76/4/447/66602>.

9. Nigwekar, S.U., S.M. Brunelli, D. Meade, et al., 2013, "Sodium Thiosulfate Therapy for Calcific Uremic Arteriolopathy," *Clinical Journal of the American Society of Nephrology*, 8(7):1162–1170.

10. Generali, J.A. and D.J. Cada, 2015, "Sodium Thiosulfate: Calciphylaxis," *Hospital Pharmacy*, 50(11):975–977.

\*11. Udomkarnjananon, S., K. Kongnatthasate, K. Praditpornsilpa, et al., 2019, "Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-Analysis," *Kidney International Reports*, 4(2):231–244.

\*12. Schulz, L.T., E.J. Elder, Jr, K.J. Jones, et al., 2010, "Stability of Sodium Nitroprusside and Sodium Thiosulfate 1:10 Intravenous Admixture," *Hospital Pharmacy*, 45(10):779–784.

Dated: July 28, 2020.

**Lowell J. Schiller,**

*Principal Associate Commissioner for Policy.*

[FR Doc. 2020–16649 Filed 7–30–20; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21, R01 Clinical Trials Not Allowed).

*Date:* August 21, 2020.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Chelsea D. Boyd, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892–9834, 301–761–6664, [chelsea.boyd@nih.gov](mailto:chelsea.boyd@nih.gov).

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21, R01 Clinical Trials Not Allowed).

*Date:* August 26, 2020.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41B, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Brenda Lange-Gustafson, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41B, Bethesda, MD 20892–9834, (240) 669–5047, [bgustafson@niaid.nih.gov](mailto:bgustafson@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: July 27, 2020.

**Tyeshia M. Roberson,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020–16585 Filed 7–30–20; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[Docket No. USCG–2020–0041]

#### National Merchant Marine Personnel Advisory Committee; Vacancy

**AGENCY:** U.S. Coast Guard, Department of Homeland Security.

**ACTION:** Request for applications; Resolicitation for members credentialed with ratings.

**SUMMARY:** The Coast Guard is resoliciting applications from persons interested in membership on the National Merchant Marine Personnel Advisory Committee (Committee). This recently established Committee will advise the Secretary of the Department

of Homeland Security on matters relating to personnel in the United States merchant marine, including the training, qualifications, certification, documentation, and fitness of mariners. Please read the notice for description of Committee positions we are seeking to fill.

**DATES:** Your completed application should reach the Coast Guard on or before August 14, 2020.

**ADDRESSES:** Applicants should send a cover letter expressing interest in an appointment to the Committee and a resume detailing their experience. We will not accept a biography.

Applications should be submitted: via the following method:

- *By Email:* Megan.C.Johns@uscg.mil. Subject Line: N-MERPAC (preferred)

**FOR FURTHER INFORMATION CONTACT:**

Megan Johns Henry, Alternate Designated Federal Officer of the Merchant Marine Personnel Advisory Committee; Telephone 202-372-1255; or Email at Megan.C.Johns@uscg.mil.

**SUPPLEMENTARY INFORMATION:** On May 15, 2020, the Coast Guard published a request in the **Federal Register** (85 FR 29467) for applications for membership in the National Merchant Marine Personnel Advisory Committee. Due to a lack of applications received for the membership positions representing credentialed ratings, the Coast Guard is re-soliciting applications from persons interested in membership on the National Merchant Marine Personnel Advisory Committee. Applicants who responded to the initial notice do not need to reapply.

The National Merchant Marine Personnel Advisory Committee is a Federal advisory committee. It will operate under the provisions of the *Federal Advisory Committee Act*, 5 U.S.C. Appendix, and the administrative provisions in Section 601 of the *Frank LoBiondo Coast Guard Authorization Act of 2018* (specifically, 46 U.S.C. 15109).

The Committee was established on December 4, 2019, by the *Frank LoBiondo Coast Guard Authorization Act of 2018*, which added section 15103, National Merchant Marine Personnel Advisory Committee, to Title 46 of the U.S. Code. The Committee will advise the Secretary of Homeland Security on matters relating to personnel in the United States merchant marine, including the training, qualifications, certification, documentation, and fitness of mariners.

The Committee is required to meet at least once a year in accordance with 46 U.S.C. 15109(a). We expect the Committee to meet at least twice a year,

but it may meet more frequently. The meetings are generally held in cities that have high concentrations of maritime personnel and related marine industry businesses.

All members serve at their own expense and receive no salary or other compensation from the Federal Government. Members may be reimbursed, however, for travel and per diem in accordance with Federal Travel Regulations.

Under provisions in 46 U.S.C. 15109(f)(6), if you are appointed as a member of the Committee, your membership term will expire on December 31 of the third full year after the effective date of your appointment. The Secretary may require an individual to have passed an appropriate security background examination before appointment to the Committee, 46 U.S.C. 15109(f)(4).

In this solicitation for Committee members, we will consider applications for positions, which include:

- United States citizens holding active licenses or certificates issued under 46 U.S.C. chapter 71 or merchant mariner documents issued under 46 U.S.C. chapter 73, including two credentialed with ratings: one of which shall be endorsed as an able bodied seaman; and one that shall be endorsed as a qualified member of the engine department.

The Department of Homeland Security does not discriminate in selection of Committee members based on race, color, religion, sex, national origin, political affiliation, sexual orientation, gender identity, marital status, disabilities and genetic information, age, membership in an employee organization, or any other non-merit factor. The Department of Homeland Security strives to achieve a widely diverse candidate pool for all of its recruitment selections.

If you are interested in applying to become a member of the Committee, send your cover letter and resume to Megan Johns Henry, Alternate Designated Federal Officer of the National Merchant Marine Personnel Advisory Committee via one of the transmittal methods in the **ADDRESSES** section by the deadline in the **DATES** section of this notice. When you send your application to us via email, we will send you an email confirming receipt of your application.

Dated: July 28, 2020.

**Jeffrey G. Lantz,**

*Director of Commercial Regulations and Standards.*

[FR Doc. 2020-16652 Filed 7-30-20; 8:45 am]

**BILLING CODE 9110-04-P**

## DEPARTMENT OF HOMELAND SECURITY

### Federal Emergency Management Agency

[Docket ID FEMA-2020-0002; Internal Agency Docket No. FEMA-B-2044]

#### Changes in Flood Hazard Determinations

**AGENCY:** Federal Emergency Management Agency, DHS.

**ACTION:** Notice.

**SUMMARY:** This notice lists communities where the addition or modification of Base Flood Elevations (BFEs), base flood depths, Special Flood Hazard Area (SFHA) boundaries or zone designations, or the regulatory floodway (hereinafter referred to as flood hazard determinations), as shown on the Flood Insurance Rate Maps (FIRMs), and where applicable, in the supporting Flood Insurance Study (FIS) reports, prepared by the Federal Emergency Management Agency (FEMA) for each community, is appropriate because of new scientific or technical data. The FIRM, and where applicable, portions of the FIS report, have been revised to reflect these flood hazard determinations through issuance of a Letter of Map Revision (LOMR), in accordance with Federal Regulations. The LOMR will be used by insurance agents and others to calculate appropriate flood insurance premium rates for new buildings and the contents of those buildings. For rating purposes, the currently effective community number is shown in the table below and must be used for all new policies and renewals.

**DATES:** These flood hazard determinations will be finalized on the dates listed in the table below and revise the FIRM panels and FIS report in effect prior to this determination for the listed communities.

From the date of the second publication of notification of these changes in a newspaper of local circulation, any person has 90 days in which to request through the community that the Deputy Associate Administrator for Insurance and Mitigation reconsider the changes. The flood hazard determination information may be changed during the 90-day period.

**ADDRESSES:** The affected communities are listed in the table below. Revised flood hazard information for each community is available for inspection at both the online location and the respective community map repository